# OnCo record paper-aza-001-fenaux-lancet-oncol-2009 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-aza-001-fenaux-lancet-oncol-2009/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-aza-001-fenaux-lancet-oncol-2009" ;
  schema:name "AZA-001: azacitidine versus conventional care in higher-risk myelodysplastic syndromes"@en ;
  schema:description "Azacitidine was the first drug shown to lengthen survival in higher-risk myelodysplastic syndromes, adding about nine months of median survival compared with the usual supportive care or chemotherapy."@en ;
  schema:url <https://onco.cc/key-papers/paper-aza-001-fenaux-lancet-oncol-2009/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(09)70003-8>, <https://pubmed.ncbi.nlm.nih.gov/19230772/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(09)70003-8> ;
  schema:datePublished "2009"^^xsd:gYear ;
  schema:author "Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al." ;
  onco:cancers <https://onco.cc/cancers/mds-higher-risk/> ;
  onco:drugs <https://onco.cc/drugs/azacitidine/> ;
  onco:trials <https://onco.cc/trials/aza-001/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .